References
[1] ZAVALA V A, KALERGIS A M.New clinical advances in immunotherapy for the treatment of solid tumours[J].Immunology, 2015, 145(2):182-201.
[2] CHRISTOFI T, BARITAKI S, FALZONE L, et al.Current perspectives in cancer immunotherapy[J].Cancers (Basel), 2019, 11(10):1472.
[3] JOHN S B, ROBERT E H, ANDREAS A H, et al.Building better chimeric antigen receptors for adoptive T cell therapy[J].Current gene therapy, 2010, 10(2): 77-90.
[4] MA S, LI X, WANG X, et al.Current progress in CAR-T cell therapy for solid tumors[J].International journal of biological sciences, 2019, 15(12):2548-2560.
[5] ZHONG X S, MATSUSHITA M, PLOTKIN J, et al.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+T cell-mediated tumor eradication[J].Mmolecular therapyol, 2010, 18(2):413-420.
[6] WILKIE S, PICCO G, FOSTER J, et al.Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor[J].Journal of immunology, 2008,180(7):4901-4909.
[7] FOURNIER C, MARTIN F, ZITVOGEL L, et al.Trial watch: adoptively transferred cells for anticancer immunotherapy[J].Oncoimmunology, 2017, 6(11): e1363139.
[8] ZHANG H, YE Z L, YUAN Z G, et al.New strategies for the treatment of solid tumors with CAR-T cells[J].International journal of biological sciences, 2016, 12(6):718-729.
[9] LUO C, WEI J, HAN W.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China[J].Science China - Life Sciences, 2016, 59(4):349-359.
[10] HU W, WANG G, HUANG D, et al.Cancer immunotherapy based on natural killer cells:current progress and new opportunities[J].Frontiers in immunology, 2019, 10:1205.
[11] ABEL A M, YANG C, THAKAR M S, et al.Natural killer cells: development, maturation,and clinical utilization[J].Frontiers in immunology, 2018, 9:1869.(https://www.daowen.com)
[12] MELISSA A G, SARAH C, PATRICIA L J, et al.A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer[J].Cytotherapy, 2011,13(1):98-107.
[13] CONGCONG Z, PRANAV O, SARAH O, et al.Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity[J].Frontiers in immunology, 2017, 8:533.
[14] FANG N, RUI S, BINQING F, et al.IGF-1 promotes the development and cytotoxic activity of human NK cells[J].Nature communications, 2013, 4:1479.
[15] TRAN A C, ZHANG D, BYRN R, et al.Chimeric zeta-receptors direct human natural killer(NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes[J].Journal of immunology, 1995, 155:1000-1009.
[16] KLINGEMANN H.Are natural killer cells superior CAR drivers?[J] Oncoimmunology,2014, 3: e28147.
[17] NISHIKAWA H, SAKAGUCHI S.Regulatory T cells in cancer immunotherapy[J].Current opinion in immunology, 2014, 27 (1):1-7.
[18] SHAHID K, KHALIFE M, DABNEY R, et al.Immunotherapy and targeted therapy-the new roadmap in cancer treatment[J].Annals of translational medicine, 2019, 7(20):595.
[19] SHAH M A, KOJIMA T, HOCHHAUSER D, et al.Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J].JAMA oncology, 2019,5(4):546-550.
[20] SHITARA K, HARA H, YOSHIKAWA T, et al.Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial[J].International journal of clinical oncology, 2020, 25(2):301-311.
[21] CHEN R, ZINZANI P L, FANALE M A, et al.Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma[J].International journal of clinical oncology, 2017, 35(19):2125-2132.
[22] PARK J H, RIVIÈRE I, GONEN M, et al.Long-term follow-up of CD19-CAR therapy in acute lymphoblastic leukemia[J].New England journal of medicine, 2018, 378(5):449-459.